Bioscience

Emerging life sciences companies grabbing more in government grantsRestricted Content

August 10, 2009
Chris O'Malley
More emerging life science companies have found life in the form of federal Small Business Innovation Research grants.
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

Dow Agrosciences introduces genetically modified corn seedRestricted Content

July 27, 2009
 IBJ Staff
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow its seed sales substantially.
More

Stem cell discovery promises health care revolutionRestricted Content

April 13, 2009
Bloomberg News
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer's disease and muscular dystrophy.
More

Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individualsRestricted Content

April 13, 2009
Chris O'Malley
Indiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to use it on the practitioner level.
More

Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cellsRestricted Content

March 23, 2009
J.K. Wall
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells.
More

Biotech push may help offset generic competition; some analysts skepticalRestricted Content

February 2, 2009
J.K. Wall
Lilly executives want to make biotech their top focus.
More

Biotech venture fund in worksRestricted Content

January 5, 2009
Peter Schnitzler
BioCrossroads is setting the stage to create Indiana Future Fund II, an effort that would raise tens of millions of dollars for speculation on promising Hoosier life science companies.
More

Report sees jackpot with BioCrossroads, but expert sees obstaclesRestricted Content

February 4, 2008
J.K. Wall
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written a report that attempts to show in detail the vast market opportunity they see.
More

IU takes statewide approach to life sciences pitchRestricted Content

January 21, 2008
J.K. Wall
For the last two months, two academics at Indiana University and Purdue University have been discussing how the institutions can work together to rev up research in medicine and life sciences and, in the process, boost Indiana's economy.
More

Ex-Lilly execs take on diabetes with Carmel startupRestricted Content

November 6, 2006
Peter Schnitzler
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies--a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.
More

Ex-prosecutor's lab biz builds network of government clientsRestricted Content

September 18, 2006
Tom Murphy
Labs are nearing capacity at Strand Analytical Laboratories, which provides forensic and paternity DNA testing. In the second year of Scott Newman's business, the former prosecutor predicts 2007 revenue will reach $4 million.
More
Page  << 1 2 3 pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT